Viet Le DMSc PA-C FACC FAHA HF-Cert Profile picture
escaped to threads @vietheartpa and bluesky: https://t.co/cMnfWksWZy

Nov 7, 2022, 6 tweets

#aha22 - SPORT trial

💊nutraceuticals ubiquitous and “assumed” by many pts to be heart healthy.
💊💰💸industry
💊 SPORT ➡️ compared to rosuva and placebo, do they impact biomarkers?
jacc.org/doi/abs/10.101…
@kewatson @ErinMichos @ljlaffin 1/

N=199, randomized single blind
💊 lipid, hsCRP, CMP. Baseline and at 28 days.
💊 1° risk, age 40-75, LDL-C 70-189, borderline to upper intermediate risk (5-20%, estimated 10 yr event)
💊 1° endpt: %LDL-C change vs rosuva
💊2° endpt: biomarkers vs rosuva; vs placebo
#aha22 2/

💊 most were at least 7.5% 10 year risk
💊 nice representation of 💃🏽
💊 LDL-C >100 (~125); hsCRP <2.0

#aha22 3/

💊 no surprise, rosuva 5 mg is potent, LDL-C %change 37 👊🏾👍🏾
💊 good to know: RYR, 6%’ish. Others nominal
💊 2° - no surprise for rosuva in TC, trigs, hdl-c

#aha22 4/

💊Some surprise by me of sterols vs statin in hscrp. What is going on cinnamon?

Placebo👀👀👀:
💊 sterols again 😏
💊 compared to placebo, supplements 🛑✋

but individual participant graphs are wicked cool to look at - flip a coin for effect

#aha22 5/

💊 not 1° or 2° endpt, but interesting side effects… looking at you musculoskeletal effects on statin - big ZERO. Placebo on other hand, 8% - samson trial anyone 😉

Summary:
Thanks for a simple, elegant study that helps in #SDM RE: statin and certain supplements #aha22 6/6

Share this Scrolly Tale with your friends.

A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.

Keep scrolling